|
|
|
| Clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window |
| LIN Shu-chun |
| Department of Neurology, Zhuanghe Central Hospital, Liaoning Province, Zhuanghe 116400, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction over thrombolysis time window. Methods A total of 96 patients with acute cerebral infarction over thrombolysis time window in Zhuanghe Central Hospital, Liaoning Province from September 2018 to March 2020 were selected as the research subjects. They were divided into a reference group (48 cases) and a joint group (48 cases)according to the random number table method. Patients in the reference group were treated with conventional symptomatic treatment + Dipyridamole via intravenous drips, while patients in the joint group were treated with conventional symptomatic treatment + Dipyridamole + Shuxuening via intravenous drips. Neurological function, limb function, daily live activity ability, efficacy, improvement of coagulation indexes and incidence of adverse reactions were compared between the two groups. Results After treatment, the scores of National Institutes of Health stroke scale (NIHSS) in the joint group were lower than those in the reference group, with statistically significant different (P＜0.05). The scores of Fugl-Meyer assessment scale (FMAS) and activity of daily living scale (ADL) in the joint group were higher than those in the reference group, the differences were statistically significant (P＜0.05). The total effective rate of the joint group was higher than that of the reference group, with statistically significant different (P＜0.05). After treatment, the prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT) in the joint group were longer than those in the reference group, and fibrinogen (FIB) in the joint group was lower than that in the reference group,the differences were statistically significant (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion The application of dipyridamole combined with Shuxuening in the treatment of acute cerebral infarction patients over thrombolysis time window has a significant effect, and the neurological function, limb function, life activity ability and coagulation indexes have been significantly improved, with few adverse reactions, which is safe and reliable.
|
|
|
|
|
|
| [1] |
周宏，叶淑萍，王丽靖，等.急性脑梗死治疗中舒血宁联合奥扎格雷钠的运用与可行性研究[J].医药论坛杂志，2018，39（1）：44-45，48.
|
| [2] |
常红云，丁彦.曲克芦丁脑蛋白水解物联合舒血宁对急性脑梗死患者神经功能及血液高凝状态的影响[J].中国药业，2018，27（23）：47-49.
|
| [3] |
陈冬，欧阳存，张淑琴，等.舒血宁注射液联合氢氯吡格雷治疗急性脑梗死的临床效果观察[J].世界中医药，2020，16（6）：887-891.
|
| [5] |
黄成兰.尤瑞克林联合舒血宁治疗对脑梗死患者NIHSS评分、疗效及预后的影响[J].中国急救医学，2018，38（2）：127.
|
| [6] |
张静，朱亚辉.舒血宁注射液联合抗血小板药物治疗急性脑梗死的疗效 观察[J].血栓与止血学，2021，27（1）：48-49，52.
|
| [7] |
杨丽.依达拉奉联合舒血宁注射液治疗急性脑梗死的效果[J].中国医药导报，2018，15（11）：74-77.
|
| [8] |
林鸿佳.阿司匹林肠溶片联合双嘧达莫治疗脑血栓的临床价值分析[J].中国现代药物应用，2020，14（24）：17-19.
|
| [4] |
代鸣明，吴志殿，苏庆杰，等.脑梗通汤联合舒血宁注射液治疗脑梗死患者临床效果观察及对患者IL-6、IL-10、TNF-α、MMP-9 水平影响[J].中药药理与临床，2018，34（2）：104-107.
|
| [9] |
郭刚，张璐璐，侯英娟，等.舒血宁注射液联合胞磷胆碱钠对脑梗死患者神经功能及血清IGF-1、vWF、HIF-1α 水平的影响[J].现代生物医学进展，2019，19（24）：4768-4771.
|
| [10] |
许玉华，王孝良.舒血宁联合依达拉奉对脑梗死患者神经功能、血清血管内皮生长因子、血清可溶性血管细胞黏附分子-1 的影响[J].中国基层医药，2019，26（19）：2351-2355.
|
| [11] |
张小明，牛宝华.阿司匹林联合双嘧达莫对脑血栓患者D 二聚体及血栓形成的影响[J].血栓与止血学，2020，26（3）：425-426.
|
| [12] |
金鑫，阴育红.双嘧达莫联合阿司匹林对脑血栓患者神经功能缺损及血液流变学的影响[J].医学理论与实践，2019，32（2）：200-201.
|
| [13] |
许玉华，王孝良.舒血宁联合依达拉奉对脑梗死患者神经功能、血清血管内皮生长因子、血清可溶性血管细胞黏附分子-1 的影响[J].中国基层医药，2019，26（19）：2351-2355.
|
| [14] |
陈勇，葛卫红，白雪.舒血宁注射液对脑梗死病人血清心型脂肪酸结合蛋白、神经元特异性烯醇化酶水平的影响[J].中西医结合心脑血管病杂志，2020，18（12）：1980-1982.
|
| [15] |
刘迪，朱秋红，刘涛生，等.双嘧达莫联合舒血宁治疗超溶栓时间窗急性脑梗死的临床疗效及凝血指标观察[J].中国现代应用药学，2020，37（10）：1214-1217.
|
|
|
|
